Efficiency and mechanism of antigen-specific CD8 + T-cell activation using synthetic long peptides

Journal of Immunotherapy

Volumn 35, Issue 2, 2012, Pages 142-153

  Zandvliet, Maarten L ^a   Kester, Michel G D ^a   Van Liempt, Ellis ^a   De Ru, Arnoud H ^a   Van Veelen, Peter A ^a   Griffioen, Marieke ^a   Guchelaar, Henk Jan ^a   Falkenburg, J H Frederik ^a   Meij, Pauline ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD8 + T cell activation; HLA class I; peptide processing; synthetic long peptides

Indexed keywords

SYNTHETIC PEPTIDE;

ARTICLE; CD8+ T LYMPHOCYTE; CELL SURFACE; CYTOSOL; ENDOPLASMIC RETICULUM; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOGENICITY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOCYTE ACTIVATION; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 84856902048     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318243f1ed     Document Type: Article

References (61)

1. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96. (Pubitemid 26332731)
2. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-386. (Pubitemid 41126955)
3. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003; 281:65-78. (Pubitemid 37324571)
4. Frentsch M, Arbach O, Kirchhoff D, et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med. 2005;11:1118-1124. (Pubitemid 41486836)
5. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the society for biological therapy. J Immunother. 2002;25: 97-138. (Pubitemid 34260764)
6. Nagorsen D, Scheibenbogen C, Thiel E, et al. Immunological monitoring of cancer vaccine therapy. Expert Opin Biol Ther. 2004;4:1677-1684. (Pubitemid 39371763)
7. Manz R, Assenmacher M, Pfluger E, et al. Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc Natl Acad Sci USA. 1995;92:1921-1925.
8. Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med. 2001;7:1159-1162. (Pubitemid 33010027)
9. Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110:201-210. (Pubitemid 47026836)
10. Kiecker F, Streitz M, Ay B, et al. Analysis of antigen-specific T-cell responses with synthetic peptides-what kind of peptide for which purpose? Hum Immunol. 2004;65:523-536. (Pubitemid 38686777)
11. Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001;75:8649-8659. (Pubitemid 32768969)
12. Meij P, Leen A, Rickinson AB, et al. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer. 2002;99:93-99. (Pubitemid 34273204)
13. Trivedi D, Williams RY, O'Reilly RJ, et al. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. 2005;105:2793-2801. (Pubitemid 40446272)
14. Zandvliet ML, Liempt EV, Jedema I, et al. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy. 2010;12: 933-944.
15. Jager E, Jager D, Karbach J, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4,0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000;191:625-630.
16. Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol. 2002;76:2634-2640. (Pubitemid 34184848)
17. Vandepapeliere P, Rehermann B, Koutsoukos M, et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine. 2005;23:2591-2601. (Pubitemid 40380803)
18. Peng H, Yang LT, Wang LY, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology. 2006;351:466-475. (Pubitemid 44108066)
19. Bioley G, Jandus C, Tuyaerts S, et al. Melan-A/MART-1- specific CD4 T cells in melanoma patients: Identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006;177:6769-6779. (Pubitemid 44715041)
20. Meddows-Taylor S, Shalekoff S, Kuhn L, et al. Development of a whole blood intracellular cytokine staining assay for mapping CD4(+) and CD8(+) T-cell responses across the HIV-1 genome. J Virol Methods. 2007;144:115-121. (Pubitemid 47103224)
21. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol. 1997; 15:821-850. (Pubitemid 27169300)
22. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002;169:350-358. (Pubitemid 34686155)
23. Bijker MS, van den Eeden SJ, Franken KL, et al. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol. 2007;179: 5033-5040.
24. Bijker MS, van den Eeden SJ, Franken KL, et al. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol. 2008;38:1033-1042.
25. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351-360. (Pubitemid 351589701)
26. Toes RE, Offringa R, Blom RJ, et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA. 1996;93:7855-7860. (Pubitemid 26277128)
27. Gnjatic S, Atanackovic D, Matsuo M, et al. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J Immunol. 2003;170: 1191-1196. (Pubitemid 36139482)
28. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6:404-414. (Pubitemid 46696551)
29. HerrW, Ranieri E, Gambotto A, et al. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci U S A. 1999;96:12033-12038. (Pubitemid 29502853)
30. Lucchiari-Hartz M, van Endert PM, Lauvau G, et al. Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J Exp Med. 2000;191:239-252. (Pubitemid 30060914)
31. Flyer DC, Ramakrishna V, Miller C, et al. Identification by mass spectrometry of CD8(+)-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product. Infect Immun. 2002;70:2926-2932. (Pubitemid 34564150)
32. Samino Y, Lopez D, Guil S, et al. A long N-terminal-extended nested set of abundant and antigenic major histocompatibility complex class I natural ligands from HIV envelope protein. J Biol Chem. 2006;281:6358-6365. (Pubitemid 43847567)
33. Escobar H, Crockett DK, Reyes-Vargas E, et al. Large scale mass spectrometric profiling of peptides eluted from HLA molecules reveals N-terminal-extended peptide motifs. J Immunol. 2008;181:4874-4882.
34. Chen Y, Sidney J, Southwood S, et al. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J Immunol. 1994;152:2874-2881. (Pubitemid 24097984)
35. Collins EJ, Garboczi DN, Wiley DC. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature. 1994;371:626-629. (Pubitemid 24315747)
36. Stryhn A, Pedersen LO, Holm A, et al. Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism. Eur J Immunol. 2000;30:3089-3099.
37. Tynan FE, Burrows SR, Buckle AM, et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol. 2005;6:1114-1122. (Pubitemid 41541789)
38. Bell MJ, Burrows JM, Brennan R, et al. The peptide length specificity of some HLA class I alleles is very broad and includes peptides of up to 25 amino acids in length. Mol Immunol. 2009;46:1911-1917.
39. Sherman LA, Burke TA, Biggs JA. Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. J Exp Med. 1992;175:1221-1226.
40. Kozlowski S, Corr M, Shirai M, et al. Multiple pathways are involved in the extracellular processing of MHC class I-restricted peptides. J Immunol. 1993;151:4033-4044. (Pubitemid 23298736)
41. AccapezzatoD,Nisini R, Paroli M, et al.Generation of anMHC class II-restricted T cell epitope by extracellular processing of hepatitis delta antigen. J Immunol. 1998;160:5262-5266. (Pubitemid 28267811)
42. Nakagawa Y, Takeshita T, Berzofsky JA, et al. Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific cytotoxic T lymphocytes. Immunology. 2000;101:76-82.
43. Sercarz EE, Maverakis E. Mhc-guided processing: Binding of large antigen fragments. Nat Rev Immunol. 2003;3:621-629. (Pubitemid 37328665)
44. Gromme M, Neefjes J. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol. 2002;39:181-202. (Pubitemid 35013511)
45. Groothuis TA, Neefjes J. The many roads to cross-presentation. J Exp Med. 2005;202:1313-1318. (Pubitemid 41668733)
46. Lizee G, Basha G, Tiong J, et al. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat Immunol. 2003;4:1065-1073. (Pubitemid 37428034)
47. Basha G, Lizee G, Reinicke AT, et al. MHC class I endosomal and lysosomal trafficking coincides with exogenous antigen loading in dendritic cells. PLoS One. 2008;3:e3247.
48. Gromme M, Uytdehaag FG, Janssen H, et al. Recycling MHC class I molecules and endosomal peptide loading. Proc Natl AcadSci U S A. 1999;96:10326-10331. (Pubitemid 29422557)
49. Kleijmeer MJ, Escola JM, Uytdehaag FG, et al. Antigen loading of MHC class I molecules in the endocytic tract. Traffic. 2001;2:124-137. (Pubitemid 32223449)
50. Faber LM, Luxemburg-Heijs SA, Willemze R, et al. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med. 1992;176:1283-1289.
51. Alexander J, Payne JA, Murray R, et al. Differential transport requirements of HLA and H-2 class I glycoproteins. Immunogenetics. 1989;29:380-388. (Pubitemid 19148804)
52. Smith KD, Lutz CT. Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells. J Immunol. 1996; 156:3755-3764. (Pubitemid 26137661)
53. van Bergen CA, Kester MG, Jedema I, et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood. 2007;109: 4089-4096. (Pubitemid 46641765)
54. Kessler JH, Benckhuijsen WE, Mutis T, et al. Competitionbased cellular peptide binding assay for HLA class I. Curr Protoc Immunol. 2004. DOI: 10.1002/0471142735.im1812s61.
55. Towne CF, York IA, Neijssen J, et al. Leucine aminopeptidase is not essential for trimming peptides in the cytosol or generating epitopes for MHC class I antigen presentation. J Immunol. 2005;175:6605-6614. (Pubitemid 41598903)
56. York IA, Bhutani N, Zendzian S, et al. Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J Immunol. 2006;177:1434-1443. (Pubitemid 44092476)
57. Griffioen M, van Egmond EH, Kester MG, et al. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica. 2009;94:1316-1320.
58. Tsukamoto S, Yokosawa H. Targeting the proteasome pathway. Expert Opin Ther Targets. 2009;13:605-621.
59. Alexander-Miller MA, Derby MA, Sarin A, et al. Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J Exp Med. 1998;188:1391-1399. (Pubitemid 28489576)
60. Oved K, Ziv O, Jacob-Hirsch J, et al. A novel postpriming regulatory check point of effector/memory T cells dictated through antigen density threshold-dependent anergy. J Immunol. 2007;178:2307-2317. (Pubitemid 46233429)
61. Zandvliet ML, Falkenburg JH, Jedema I, et al. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy. J Immunother. 2009;32:513-523.